Latest Regulatory Pathways News

Page 1 of 36
Aureka has completed its $8.9 million acquisition of the operating Fiddlers Creek mine and Wedderburn processing mill, moving from explorer to producer. The company now faces the harder test: turning spare mill capacity and a small-scale mine into dependable cash generation.
Maxwell Dee
Maxwell Dee
16 Nov 2026
Cleo Diagnostics has commissioned three Ella immunoassay instruments at a US laboratory as it prepares to begin the final major clinical testing program for its pre-surgical ovarian cancer test. The approximately 1,470-sample program is intended to support a planned FDA 510(k) submission in the first half of calendar 2027, but no clinical results have yet been reported.
Ada Torres
Ada Torres
12 Nov 2026
Starpharma is targeting a December start for first-in-human testing of its lead DEP HER2-Lu radiopharmaceutical, subject to ethics approval, as it shifts decisively toward targeted oncology. The company also outlined stronger funding, majority ownership of Petalion’s FAP program and a proposed Chair transition at its 2026 AGM.
Ada Torres
Ada Torres
6 Nov 2026
Aureka has secured a seven-year Prospecting Licence for its Comstock gold and silver project near St Arnaud, Victoria, creating a regulatory pathway to assess a return to mining at the historically disturbed site. The approval does not authorise mining, with further consents, work-plan approval, technical studies and funding still required.
Maxwell Dee
Maxwell Dee
5 Nov 2026
Theta Gold Mines has reached approximately 72% plant construction at its TGME Gold Project in South Africa and completed its first US$37 million bond drawdown. The company continues to target first gold in the first quarter of 2027, although further funding releases, commissioning and regulatory steps remain ahead.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Invex Therapeutics has paired its proposed acquisition of Rekover Therapeutics with a $10 million equity raising to fund a Phase 2a multiple sclerosis study and its existing Exenatide programs. The biotech ended September with A$3.59 million in cash, with shareholder approval still required for the larger part of the transaction.
Ada Torres
Ada Torres
30 Oct 2026
Australian Vanadium has moved its flagship project closer to an Optimised Feasibility Study while adding new industrial battery opportunities with Alcoa. But the September quarter also reduced cash to $12.4 million, leaving an estimated 2.5 quarters of funding at the reported spending rate.
Victor Sage
Victor Sage
30 Oct 2026
Magnum Mining has completed its main Piracanjuba North drilling campaign and narrowed the Brazilian rare earths project to a 32.5 square kilometre priority zone ahead of a maiden resource estimate. The progress comes with a sharper constraint: A$2.0 million in cash covers only about 1.19 quarters at the latest spending rate.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Vectus Biosystems has secured FDA acceptance of a pre-IND Type B meeting for VB0004, a key regulatory step for its idiopathic pulmonary fibrosis programme. The biotech ended September with $410,000 in cash and reported estimated funding for just 1.33 quarters of operations.
Ada Torres
Ada Torres
29 Oct 2026
Skin Elements has converted its New Zealand Farmlands agreement into a first NZ$150,000 ECO-Nurture delivery, while A$900,000 in placement proceeds lifted quarter-end cash to A$1.455 million. The commercial progress comes alongside a cost review and a regulatory hurdle still standing between the company and broader national sales.
Ada Torres
Ada Torres
29 Oct 2026
Siren Gold has applied to reclaim the Sams Creek ground, advanced permit and access applications across New Zealand, and raised A$799,000 by selling part of its RUA Gold stake. The progress comes with only A$596,000 in cash at quarter end, leaving the company reliant on project approvals and potential further funding options.
Maxwell Dee
Maxwell Dee
29 Oct 2026
Biotron’s BIT-HBV001 produced up to a 99.7% reduction in HBV-DNA in cell-based studies, while combination testing with Myrcludex B showed antiviral synergy. The company is also refining SedRx’s European regulatory pathway, but had A$1.06 million in cash at quarter-end, equivalent to 2.15 quarters of funding at the latest operating burn rate.
Ada Torres
Ada Torres
28 Oct 2026

Browse the archive

Full archive